Business Information
The group's principal activity is to discover, develop and market small molecule drugs and recombinant proteins. Its current product candidates are primarily for the treatment of bone and mineral disorders, gastrointestinal disorders and central nervous system disorders. The group's drug candidates in active clinical development and preclinical stages include preos (TM) for treating osteoporosis, alx-0600 for treating gastrointestinal disorders and amg 073 for treating hyperparathyroidism. The group has collaborative research and development agreements with amgen inc, kirin brewery company, ltd, glaxosmithkline and astrazeneca ab. It has licensing agreements with eli lilly and company for technology related to excitatory amino acid receptor antagonists to treat pain, and with janssen. Pharmaceutica nv for technology related to glycine reuptake inhibitors to treat schizophrenia. The group operates in the United States and Canada.
|
|
Name |
Title
|
Email
|
| Gerard Michel | CFO | N/A | | Alan Mueller | VP - Drug Discovery | N/A | | Francois Nader | COO, Exec. VP | N/A | | Gregory Torre | Sr. VP - Regulatory Affairs | N/A | | Val Antczak | Sr. VP - Legal Affairs, General Counsel | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 48,502 | (112,668) | | 2005 | 12,825 | (169,723) | | 2004 | 14,237 | (168,251)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
